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Allergic rhinitis is a common problem in childhood and adolescence, with a negative impact on the quality of life of
patients and their families. The treatment modalities for allergic rhinitis include allergen avoidance, anti-inflammatory
symptomatic treatment and allergen specific immunotherapy. In this review, four cases of children with allergic rhinitis are
presented to illustrate how the recently published EAACI Guidelines on Pediatric Allergic Rhinitis can be implemented in
clinical practice.
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Allergic rhinitis is a common problem in childhood and
adolescence [1]. This is partly the reason why it is often
under perceived by patients and families, under diagnosed
and its impact underestimated. Allergic rhinitis causes
chronic disturbing symptoms which have a negative effect
on physical, social and psychological well-being, as well as
on school performance of children and teenagers [2-4].
There are multiple associated co-morbidities [5], which
further contribute to the direct and indirect costs of rhin-
itis [6]. Recently, a European Academy of Allergy and
Clinical Immunology (EAACI) position paper on pediatric
rhinitis was published to address the need for guidance on
the management of this condition in the pediatric age
group [7]. The main treatment modalities for pediatric al-
lergic rhinitis include: avoidance of the relevant allergens,
symptomatic treatment with H1-anti-histamines, intrana-
sal corticosteroids and oral leukotriene-receptor antago-
nists, and allergen-specific immunotherapy (Figure 1). In
this review article, we have used four pediatric cases to il-
lustrate key aspects of the treatment of pediatric allergic* Correspondence: g.c.roberts@soton.ac.uk
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unless otherwise stated.rhinitis as an exercise to help implementing the aforemen-
tioned EAACI guidelines in clinical practice.Case 1
The importance of patient education and of a good nasal
spray technique
Six-year-old girl presented to clinic in June with trouble-
some hay fever symptoms. She had significant nasal ob-
struction and pruritus, sneezing and watery nasal discharge.
The symptoms had started in early April and were progres-
sively worsening. In previous years, she had had similar
symptoms from April to July, but was asymptomatic during
the rest of the year. Her doctor had prescribed oral cetiri-
zine and intranasal mometasone furoate about 4 weeks
after the symptoms started, but this treatment did not
result in significant improvement. She stopped using the
intranasal corticosteroid two weeks later because she was
having frequent nose bleeds and had developed nasal crust-
ing that she associated with the use of the nasal spray.
Skin prick testing was positive to grass pollens and
negative to other common airborne allergens. After check-
ing the patient’s nasal spray technique, the allergy clinic
team realised that she was not using it properly and spent
some time providing appropriate training.
The patient was prescribed a very short course of rescue
decongestant to open up her congested nasal airway and
intranasal isotonic saline to minimise the formation of
nasal crusting. She was advised to use daily intranasalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Treatment of allergic rhinitis (7). The entry points into therapeutic approach depend on the severity of the rhinitis symptoms.
Therapy can be step up or step down depending on control obtained in response to the treatment. If less than 2 years of age and do not
respond to antihistamine within a week, the diagnosis should be reconsidered before stepping up therapy. *Oral antihistamines may be better
tolerated, whilst intranasal antihistamines have a more rapid onset of action. **Reconsider diagnosis if not controlled within 1-2 weeks.
Santos et al. Clinical and Translational Allergy  (2015) 5:2 Page 2 of 6mometasone furoate and cetirizine until the end of the
pollen season, whilst attempting to minimise direct exposure
to grass pollen. Her family was educated to start cetirizine
and intranasal corticosteroids about 2 weeks before the be-
ginning of the grass pollen season in the following years.
Case 1 highlights the importance of adherence to treat-
ment and of a correct application technique of the nasal
spray for maximum effect and for minimising side effects.
Nasal drops and nasal sprays require different techniques
(Figure 2) [8]. Poor technique is a common cause of treat-
ment failure, so it is important to spend time in clinic
explaining the appropriate use of these devices and pro-
viding hands-on training [9]. It is also important to ex-
plain the nature of the treatment, its safety profile and
possible side effects. Patients should be given realistic ex-
pectations about the results of the treatment and should
be informed that complete resolution does not usually
occur in the treatment of chronic conditions such as aller-
gic rhinitis. For example, in the case of intranasal cortico-
steroids, patients should be informed that they take a few
days before any effects can be noticed. Appropriate infor-
mation helps in ensuring concordance with therapy, which
is critical for a good control of the nasal inflammation and
for the improvement of the symptoms.
Minimising allergen exposure is also an important
part of the management of this condition. Given her
grass pollen allergy, she was advised to minimize early
morning and evening activities outdoors, to avoid going
out after thunderstorms or on windy days during the
pollen season, to wear sunglasses when outside, to avoid
mowing the grass or being near it when it is being
mowed, to keep windows closed as much as possible
and use air-conditioning and to wash her hair at the end
of the day when she arrives home as well as to bathe her
eyes and douche her nose frequently during the grass
pollen season.Finally, pollen levels rise slowly at the start of the
pollen season with symptoms only presenting at a
threshold level. Prior to this, exposure to small amounts
of allergen will attract inflammatory cells into the nasal
airway exacerbating symptoms when pollen levels rise
further. Commencing hayfever treatment a few weeks
prior to the expected start of the seasons, can be very
helpful in delaying symptom onset and in achieving
symptom control.
Case 2
The role of anti-leukotrienes in the treatment of allergic
rhinitis
An 8-year-old boy was referred to the Allergy clinic due
to nasal symptoms consisting of rhinorrhoea, sneezing
and nasal itching since he was 5. His parents reported
that the symptoms usually persisted throughout the
year, worsened during the winter, particularly with ex-
posure to house dust, but had not disturbed his sleep or
daily activities. While exercising, he usually developed
wheeze and cough that subsided with rest. His physical
examination was normal and skin prick tests were posi-
tive for house dust mite (HDM). Allergen avoidance and
a once daily, non-sedative H1-antihistamine (deslorata-
dine) resulted in improvement of the nasal symptoms
but his exercise-induced complaints persisted. An anti-
leukotriene (montelukast) was therefore added resulting
in better control of the lower respiratory symptoms.
This patient had classic symptoms and signs of aller-
gic rhinitis with rhinorrhoea, pruritus and sneezing. The
presence of allergic sensitization to HDM suggests a
diagnosis of allergic rhinitis.
According to the Allergic Rhinitis and its Impact on
Asthma (ARIA) guidelines [10], his rhinitis would be
classified as persistent based on the duration of symp-
toms and mild according to the impact of the disease
Figure 2 The use of an appropriate technique for (a) application of nasal spray and (b) installation of nasal drops (8) is key for the
success of the treatment.
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Various studies have shown that rhinitis and bronchial
hyper-reactivity frequently co-exist in children [11-14]
and that treatment of rhinitis can improve asthma con-
trol [15].
Allergen avoidance measures and anti-histamine ther-
apy led to partial clinical improvement. It has been re-
ported that allergen avoidance should be the first
intervention for allergic rhinitis although interventional
studies suggest that it is of limited value for allergens
such as house dust mite. Regarding therapy, antihista-
mines can be used as first-line therapy, although nasalcorticosteroids are more effective particularly in reducing
mucosal oedema and may also have beneficial effects on
asthma [13,15-19]. Nevertheless, antihistamines may be
preferred in mild rhinitis, especially if there is no nasal
obstruction, as in this case. Adding montelukast to the
treatment improved symptom control. Anti-leukotriene
receptor antagonists have been shown to be effective for
controlling exercise-induced asthma and preventing the
seasonal decrease in lung function parameters in pa-
tients with grass pollen allergy [20]. They may be used
as add-on therapy to control rhinitis in patients with
concomitant asthma [13,16-19].
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The treatment of coexisting conjunctivitis in allergic rhinitis
A 10 year-old girl was referred to the Allergy outpatient
clinic for rhino-conjunctivitis of one year’s duration. Her
symptoms of rhinorrhoea, nasal blockage, sneezing and
itching started when she was 7. She reported that her
symptoms only occurred from March to June. They had
now worsened with the addition of bilateral ocular prur-
itus, conjunctival hyperaemia and watering eyes. During
these episodes she could not do her usual daily activities
outdoors and did not sleep well. Physical examination was
normal and skin prick tests were positive for grass pollen.
Considerable improvement occurred with allergen avoid-
ance and oral levocetirizine once daily. After adding a nasal
corticosteroid (mometasone furoate) once a day to the
treatment, complete clinical remission occurred with good
control of both ocular and nasal symptoms.
In the presence of rhinorrhoea, nasal obstruction, pruritus
and sneezing [21] which develop seasonally and sensitization
to pollen [10], a diagnosis of allergic rhinitis was made. Ac-
cording to the ARIA guidelines [10], it was classified as per-
sistent rhinitis, since symptoms occurred more than 4 days
a week and more than 4 weeks a year and as moderate/se-
vere, since it affected her daily activities and sleep [10]. This
case highlights that despite having only seasonal symptoms,
patients can present with persistent moderate-severe rhin-
itis, which has implications for therapy.
This child also had allergic conjunctivitis, with bilateral
ocular pruritus, hyperaemia and watery eyes, which is very
common in patients with pollen-induced allergic rhinitis.
Allergic conjunctivitis is the commonest co-morbidity as-
sociated with allergic rhinitis [22].
As described before, minimization of contact with the
relevant allergens should be the first-line intervention. So,
she was advised to avoid outdoor activities during the pe-
riods of high pollen count, to wear sunglasses when out-
side and to open the windows only during the evening
and night.
Nasal corticosteroids were prescribed, ameliorating nasal
and ocular symptoms. Nasal corticosteroids are considered
to be the most effective treatment to control nasal inflam-
mation in moderate to severe allergic rhinitis [13,16-18],
especially in the presence of nasal obstruction [7,18]. More-
over, some studies have shown that fluticasone furoate and
mometasone furoate improve conjunctivitis since some of
the eye symptoms result from nasal inflammation and
nasal-ocular reflex activation [23]. A recent systematic
review and meta-analysis suggest that leukotriene receptor
antagonists may also have a beneficial effect in ocular symp-
toms of seasonal allergic rhinitis [24].
Nasal corticosteroids are well tolerated, being recom-
mended for children and adolescents with allergic rhinitis,
from the age of two [23,25-27]. Newer nasal corticosteroids
(e.g. fluticasone propionate [28], mometasone furoate [29])are safe, and do not impair growth velocity [30], as opposed
to older nasal corticosteroids, such as beclomethasone and
budesonide. However, a recent study shows small impair-
ment of growth with fluticasone furoate administered over a
one-year period to prepubescent children with perennial al-
lergic rhinitis [31]. Therefore, when prescribing nasal corti-
costeroids to children, one should balance the benefits and
risks, prefer the ones with documented fewer adverse effects
and explain to parents the safety and efficacy of this treat-
ment in order to avoid loss of adherence to therapy and
“steroid-phobia”.
Finally, non-sedative antihistamines are useful as add-
on therapy to nasal corticosteroids [7,10,16-18,32] and
were prescribed for this patient with good results. First-
generation antihistamines are not recommended for the
treatment of allergic rhinitis as they cause sedation and
may affect cognitive function and reduce academic and/
or work performance [2,33].
Case 4
The role of allergen specific immunotherapy in the
treatment of allergic rhinitis in children
Twelve-year-old boy presented with very disruptive
symptoms of rhinitis with significant nasal obstruction
as well as sneezing, rhinorrhoea and very disturbing
nasal and ocular pruritus. These symptoms developed
every year during the summer months and were persist-
ent and severe, affecting his ability to sleep and his per-
formance at school. His exam marks were lower in his
summer examinations compared to those earlier in the
year. He also felt that his nose problems were restricting
his sport and social activities during the period when the
weather was good; he liked playing outside. He was
tested for different airborne allergens and both skin and
specific IgE testing showed sensitization to grass pollen
confirming grass pollen allergy. The previous years, he
had been prescribed loratadine, intranasal mometasone
furoate, montelukast and sodium cromoglicate eye
drops, which he was taking. Despite good adherence, he
continued to have poor disease control.
Given his continued symptoms, that were impacting
on this quality of life, despite optimal pharmacotherapy,
he was started on sublingual immunotherapy to grass
pollen. He took the first dose in clinic and continued
with the treatment at home. He initially had some local
pruritus but this settled after a couple of weeks. One
year into this treatment, he was already feeling some im-
provement and was able to reduce the medication he
was taking to loratadine only.
Allergen-specific immunotherapy (IT) is the only disease-
modifying treatment for allergic rhinitis. It is able to change
the natural history of this condition and to provide long-
term remission [34,35]. It is indicated in patients over
5 years old with demonstrable IgE to clinically relevant
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treatment has failed to control symptoms [36]. Since he was
having troublesome symptoms despite maximum pharma-
cological therapy and the symptoms were due to grass
pollen exposure to which he had detectable IgE, he was a
good candidate for this treatment. There are standardized
extracts to grass pollen commercially available to administer
via the subcutaneous or the sublingual route [37,38].
Although there are very few head-to-head studies compar-
ing subcutaneous immunotherapy (SCIT) and sublingual
immunotherapy (SLIT), both forms are effective if appropri-
ately used [39,40]. In terms of safety, SCIT more frequently
causes systemic adverse events while SLIT tends to cause
more local side effects, which are usually mild and resolve
with continuation of treatment [41,42]. Severe adverse
events are commonly associated with uncontrolled asthma,
high allergen exposure during therapy, concomitant diseases
such as severe infections and inexperienced health care staff.
Premedication with an antihistamine may decrease the rate
of adverse effects [43]. The decision on whether to do SLIT
or SCIT depends on a variety of factors, including patient’s
preference about home-based versus hospital-based treat-
ment, fear of injections, costs and concordance.[44]. In chil-
dren, SLIT is more widely accepted but may have lower
patient adherence [45]. Although SLIT is given at home, the
first dose should be given at the doctor’s office. This is also
the opportunity to give detailed instructions about how to
administer the treatment and about the precautions to be
taken. Patients should be informed about possible adverse
reactions and about the ways to treat them. Apart from the
effectiveness in reducing symptoms and medication use, an-
other potential advantage of allergen-specific immunother-
apy is its preventative effects in reducing asthma and the
development of further allergic sensitizations [46-50]. This is
particularly important in the pediatric age groups. When
clinically indicated, IT should be started early in the disease
process, before significant remodelling and fixed airway
obstruction has developed in the case of patients with
asthma. As allergen-specific immunotherapy is the only
disease-modifying treatment available for allergic rhinitis
and respiratory allergy, it may be considered as a therapeutic
option even before trying maximal therapy, depending on
individual cases, clinical practice and finance.
Conclusions
1. Patient education and appropriate nasal device
training are very important for an effective and safe
treatment of allergic rhinitis in children.
2. Allergen avoidance is part of the treatment of
allergic rhinitis.
3. Symptomatic relief and reduction of nasal
inflammation may be obtained with nasal
corticosteroids, which are globally the mosteffective therapy. Oral anti-histamines and
anti-leukotrienes can also prove effective.
4. Allergen-specific immunotherapy is the only
disease-modifying treatment for allergic rhinitis and
has the potential to prevent the development of
further allergic sensitization and asthma.
Abbreviations
ARIA: Allergic rhinitis and its impact on asthma; EAACI: European Academy of
Allergy and Clinical Immunology; HDM: House dust mite; IT: Immunotherapy;
SCIT: Subcutaneous immunotherapy; SLIT: Sublingual immunotherapy.
Competing interests
GS has received research grants from GSK, ALK; honoraria for articles,
consulting, lectures/ chairing and/or advisory boards from ALK, Bausch &
Lomb, Church & Dwight, Circassia, GSK, Groupo Uriach, Meda, Merck, Ono,
Shionogi, Stallergenes.
The other authors declared no competing interests.
Authors’ contributions
GR designed the manuscript, AFS and LMB wrote the first draft and all
authors commented on the manuscript and accepted the final version.
All authors read and approved the final manuscript.
Author details
1Department of Paediatric Allergy, Division of Asthma, Allergy & Lung
Biology, King’s College London, London, UK. 2MRC & Asthma UK Centre in
Allergic Mechanisms of Asthma, London, UK. 3Immunoallergology
Department, Coimbra University Hospital, Coimbra, Portugal. 4CUF
Descobertas Hospital, Lisbon, Portugal. 5CEDOC, Nova Medical School,
Universidade Nova de Lisboa, Lisbon, Portugal. 6The Royal National Throat,
Nose and Ear Hospital & University College London Hospitals, London, UK.
7David Hide Asthma and Allergy Research Centre, St Mary’s Hospital, Isle of
Wight, UK. 8Human Development and Health and Clinical Experimental
Sciences Academic Subunits, University of Southampton Faculty of Medicine,
Southampton, UK. 9Respiratory Biomedical Research Unit, University Hospital
Southampton NHS Foundation Trust, Southampton, UK. 10Paediatric Allergy
and Respiratory Medicine, University Child Health (MP803), University
Hospital Southampton NHS Foundation Trust, Southampton, UK.
Received: 17 September 2014 Accepted: 30 December 2014
References
1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al.
Worldwide time trends in the prevalence of symptoms of asthma, allergic
rhinoconjunctivitis, and eczema in childhood: ISAAC Phases one and three
repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43.
2. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal
allergic rhinitis is associated with a detrimental effect on examination
performance in United Kingdom teenagers: case-control study. J Allergy Clin
Immunol. 2007;120(2):381–7.
3. Silva CH, Silva TE, Morales NM, Fernandes KP, Pinto RM. Quality of life in
children and adolescents with allergic rhinitis. Braz J Otorhinolaryngol.
2009;75(5):642–9.
4. Roberts G, Hurley C, Lack G. Development of a quality-of-life assessment for
the allergic child or teenager with multisystem allergic disease. J Allergy Clin
Immunol. 2003;111(3):491–7.
5. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin
Immunol. 2001;108(1 Suppl):S9–15.
6. Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P,
et al. Allergic rhinitis management pocket reference 2008. Allergy.
2008;63(8):990–6.
7. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW,
et al. Paediatric rhinitis: position paper of the European academy of allergy
and clinical immunology. Allergy. 2013;68(9):1102–16.
8. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, et al.
BSACI guidelines for the management of allergic and non-allergic rhinitis.
Clin Exp Allergy. 2008;38(1):19–42.
Santos et al. Clinical and Translational Allergy  (2015) 5:2 Page 6 of 69. Gani F, Pozzi E, Crivellaro MA, Senna G, Landi M, Lombardi C, et al. The role
of patient training in the management of seasonal rhinitis and asthma:
clinical implications. Allergy. 2001;56(1):65–8.
10. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al.
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in
collaboration with the World Health Organization, GA (2) LEN and AllerGen).
Allergy. 2008;63 Suppl 86:8–160.
11. Kurukulaaratchy RJ, Raza A, Scott M, Williams P, Ewart S, Matthews S, et al.
Characterisation of asthma that develops during adolescence; findings from
the Isle of wight birth cohort. Respir Med. 2012;106(3):329–37.
12. Hamouda S, Karila C, Connault T, Scheinmann P, de Blic J. Allergic rhinitis in
children with asthma: a questionnaire-based study. Clin Exp Allergy. 2008;38
(5):761–6.
13. Ballardini N, Kull I, Lind T, Hallner E, Almqvist C, Ostblom E, et al.
Development and comorbidity of eczema, asthma and rhinitis to age 12:
data from the BAMSE birth cohort. Allergy. 2012;67(4):537–44.
14. Kurukulaaratchy RJ, Fenn M, Matthews S, Arshad SH. Characterisation of
atopic and non-atopic wheeze in 10 year old children. Thorax.
2004;59(7):563–8.
15. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma
outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013;68(5):569–79.
16. Anolik R. Clinical benefits of combination treatment with mometasone
furoate nasal spray and loratadine vs monotherapy with mometasone
furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma
Immunol. 2008;100(3):264–71.
17. Martin BG, Andrews CP, van Bavel JH, Hampel FC, Klein KC, Prillaman BA,
et al. Comparison of fluticasone propionate aqueous nasal spray and oral
montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann
Allergy Asthma Immunol. 2006;96(6):851–7.
18. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C,
et al. Randomized placebo-controlled trial comparing fluticasone aqueous
nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus
montelukast and cetirizine plus montelukast for seasonal allergic rhinitis.
Clin Exp Allergy. 2004;34(2):259–67.
19. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a
century of progress. J Allergy Clin Immunol. 2011;128(6):1139–50. e1134.
20. Keskin O, Alyamac E, Tuncer A, Dogan C, Adalioglu G, Sekerel BE. Do the
leukotriene receptor antagonists work in children with grass pollen-induced
allergic rhinitis? Pediatr Allergy Immunol. 2006;17(4):259–68.
21. Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D, et al.
BSACI guidelines for the management of rhinosinusitis and nasal polyposis.
Clin Exp Allergy. 2008;38(2):260–75.
22. Bjorksten B, Clayton T, Ellwood P, Stewart A, Strachan D. Worldwide time
trends for symptoms of rhinitis and conjunctivitis: phase III of the
international study of asthma and allergies in childhood. Pediatr Allergy
Immunol. 2008;19(2):110–24.
23. Anolik R, Nathan RA, Schenkel E, Danzig MR, Gates D, Varghese S. Intranasal
mometasone furoate alleviates the ocular symptoms associated with seasonal
allergic rhinitis: results of a post hoc analysis. Int Arch Allergy Immunol. 2008;147
(4):323–30.
24. Gane J, Buckley R. Leukotriene receptor antagonists in allergic eye disease: a
systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2013;1(1):65–74.
25. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and
effective for 1-year treatment of children with perennial allergic rhinitis.
Int J Pediatr Otorhinolaryngol. 2009;73(5):651–7.
26. Wandalsen GF, Mendes AI, Sole D. Objective improvement in nasal
congestion and nasal hyperreactivity with use of nasal steroids in persistent
allergic rhinitis. Am J Rhinol Allergy. 2010;24(1):e32–6.
27. Nathan RA, Berger W, Yang W, Cheema A, Silvey M, Wu W, et al. Effect of once-
daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents
with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(5):497–505.
28. Allen DB, Meltzer EO, Lemanske Jr RF, Philpot EE, Faris MA, Kral KM, et al. No
growth suppression in children treated with the maximum recommended
dose of fluticasone propionate aqueous nasal spray for one year.
Allergy Asthma Proc. 2002;23(6):407–13.
29. Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability
of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Eur J Clin Pharmacol. 2004;60(4):265–8.
30. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM,
et al. Detection of growth suppression in children during treatment with
intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23.31. Lee LA, Sterling R, Maspero J, Clements D, Ellsworth A, Pedersen S. Growth velocity
reduced with once-daily fluticasone furoate nasal spray in prepubescent children
with perennial allergic rhinitis. J Allergy Clin Immunol Pract. 2014;2(4):421–7.
32. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, et al.
Evaluating approved medications to treat allergic rhinitis in the United
States: an evidence-based review of efficacy for nasal symptoms by class.
Ann Allergy Asthma Immunol. 2010;104(1):13–29.
33. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF.
Seasonal allergic rhinitis and antihistamine effects on children’s learning.
Ann Allergy. 1993;71(2):121–6.
34. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al.
Five-year follow-up on the PAT study: specific immunotherapy and long-
term prevention of asthma in children. Allergy. 2006;61(7):855–9.
35. Calderon MA, GerthvanWijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV,
et al. Perspectives on allergen-specific immunotherapy in childhood: an
EAACI position statement. Pediatr Allergy Immunol. 2012;23(4):300–6.
36. Bufe A, Roberts G. Specific immunotherapy in children. Clin Exp Allergy.
2011;41(9):1256–62.
37. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al. Efficacy
and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric
allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160–6. e163.
38. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al.
Safety and efficacy in children of an SQ-standardized grass allergen tablet
for sublingual immunotherapy. J Allergy Clin Immunol.
2009;123(1):167–73. e167.
39. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen
injection immunotherapy for seasonal allergic rhinitis. Cochrane Database
Syst Rev. 2007;1, CD001936.
40. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of
sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740–52.
41. Vance GH, Goldring S, Warner JO, Cox H, Sihra B, Hughes S, et al. A national
audit of pollen immunotherapy for children in the United Kingdom: patient
selection and programme safety. Clin Exp Allergy. 2011;41(9):1313–23.
42. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, et al. Safety
of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann
Allergy Asthma Immunol. 2005;95(3):254–8.
43. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication
reduces the incidence of systemic reactions during inhalant rush immunotherapy
with mixtures of allergenic extracts. Ann Allergy. 1994;73(5):409–18.
44. Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H,
et al. GA (2) LEN/EAACI pocket guide for allergen-specific immunotherapy for
allergic rhinitis and asthma. Allergy. 2010;65(12):1525–30.
45. Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to
sublingual immunotherapy prescriptions are patients? The manufacturers’
viewpoint. J Allergy Clin Immunol. 2010;126(3):668–9.
46. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific
immunotherapy has long-term preventive effect of seasonal and perennial asthma:
10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8.
47. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y.
Prevention of new sensitizations by specific immunotherapy in children
with rhinitis and/or asthma monosensitized to house dust mite. J Investig
Allergol Clin Immunol. 2007;17(2):85–91.
48. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J.
Immunotherapy with a standardized Dermatophagoides pteronyssinus
extract. VI. Specific immunotherapy prevents the onset of new sensitizations
in children. J Allergy Clin Immunol. 1997;99(4):450–3.
49. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new
sensitizations in asthmatic children monosensitized to house dust mite by specific
immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31(9):1392–7.
50. Purello-D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P,
Parmiani S, et al. Prevention of new sensitizations in monosensitized
subjects submitted to specific immunotherapy or not. A retrospective study.
Clin Exp Allergy. 2001;31(8):1295–302.
